Form 4: Eterna Therapeutics Director James Arthur Bristol Acquires Stock Options
SEC Form 4 Filing
Director James Arthur Bristol acquired 72,074 stock options in Eterna Therapeutics on February 7, 2025.
Summary
- James Arthur Bristol, a director of Eterna Therapeutics Inc., acquired 72,074 stock options on February 7, 2025.
- The options have an exercise price of $0.34.
- The options vest over time, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in 24 equal monthly installments.
- The expiration date for the options is February 7, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The director's acquisition could be interpreted as a slightly positive signal.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of transaction: Director James Arthur Bristol acquired stock options. |
| 02/10/2025 | Date of signature on the Form 4 filing. |
| 02/07/2035 | Expiration date of the stock options. |
Keywords
stock options, director, acquisition, Eterna Therapeutics, ERNA, Form 4, beneficial ownership, James Arthur Bristol
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.